The Advanced Lupus Test
Powered by CB-CAPs Technology
AVISE® Lupus is a 10-marker diagnostic test containing Cell-Bound Complement Activation Products (CB-CAPs) and SLE associated markers designed to aid healthcare providers in a timely differential diagnosis of SLE.
|Biomarkers||AVISE Lupus||AVISE CTD|
|10-marker Lupus diagnostic test containing Cell-Bound Complement Activation Products (CB-CAPs)|
|AVISE Index Calculation Value|
|Extractable Nuclear Antigen (ENA) Panel|
|Rheumatoid Arthritis Panel|
|Antiphospholipid Syndrome – APS panel|
AVISE Lupus contains the following biomarkers:
AVISE® Lupus contains patented Lupus (SLE) biomarkers, CB-CAPs, which help to offer a 22% greater sensitivity than C3/C4, and 48% greater sensitivity than anti-dsDNA.
Clinical Utility: AVISE Lupus Test Report
The AVISE Lupus test is an ideal test for ANA positive patients with a clinical suspicion of lupus.
Testing method: The AVISE Lupus test is composed of a two-tier testing method
- Cell-bound complement activation products in SLE. Ramsey-Goldman R, et al. Lupus Science and Medicine. 2017.
- Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Putterman C. et al. Lupus Science and Medicine. 2014.
- Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Wallace D. et al. Lupus Science & Medicine. 2016.
- The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Mossell J. et al. The Open Rheumatology Journal. 2016.